Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach.

Kızılırmak P., Öngen Z., Güleç S., Kayıkçıoğlu M., Kılıçkap M., Abacı A., ...Daha Fazla

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, cilt.50, ss.554-560, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5543/tkda.2022.22367
  • Dergi Adı: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.554-560
  • Anahtar Kelimeler: Cardiovascular risk factors, Delphi, LDL-cholesterol, PCSK9 inhibitor, Turkey, LDL-C, METAANALYSIS, PREVALENCE, EVOLOCUMAB
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study is to analyze the low-density lipoprotein cholesterol-lowering therapies in secondary prevention patients by anatyzing their plasma low-density lipoprotein cholesterol levels. current treatment, considering their inadequate response to medications (as defined in current guidelines), and the requirement for a protein convertase subtilisin/kexin type 9 inhibitor.